CUE CUE
Company Profile ↓Company Overview
CUE (CUE) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 57.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $27.47M (+195.7% YoY); net profit $-26.60M.
- Trailing 12 Months Year-on-year growth — revenue +195.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 57.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 57.50% |
| 1 Year: | 195.75% |
Stock Price Performance
| 1 Year: | +16.58% |
| 6 Months: | +169.19% |
| 3 Months: | -23.73% |
| 1 Month: | -20.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 57.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 27.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 172.00K | 449.00K | 370.00K | 1.05M | 984.00K | 900.00K | 1.07M | 704.00K | 1.55M | 2.74M | 2.40M | 1.00M | 26.00K | 68.00K | 187.00K | 1.38M | 2.10M | 1.72M | 2.66M | 3.34M | 421.00K | 2.95M | 2.15M | 5.69M |
| Operating Income | -3.35M | -4.41M | -5.03M | -7.52M | -7.47M | -12.76M | -11.43M | -9.23M | -7.09M | -12.99M | -10.94M | -10.13M | -12.52M | -10.30M | -13.02M | -14.24M | -13.09M | -11.03M | -13.38M | -13.52M | -11.42M | -12.67M | -10.38M | -8.81M | -12.30M | -8.63M | -7.59M | -5.35M |
| Net Income | -3.35M | -4.41M | -5.03M | -7.52M | -7.30M | -12.56M | -11.27M | -9.52M | -6.99M | -12.82M | -10.83M | -10.03M | -12.51M | -10.28M | -12.99M | -14.26M | -13.21M | -10.96M | -13.11M | -13.19M | -11.01M | -12.35M | -10.17M | -8.66M | -12.26M | -8.48M | -7.45M | -5.18M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.41 | -0.44 | -0.37 | -0.31 | -0.29 | -0.29 | -0.24 | -0.25 | -0.20 | -0.17 | -4.95 | -0.09 | -0.07 | -1.08 |
| R&D Expense | 2.46M | 3.42M | 4.00M | 5.82M | 5.41M | 10.31M | 8.35M | 6.87M | 5.30M | 9.91M | 8.12M | 7.52M | 9.82M | 8.76M | 11.29M | 10.08M | 9.59M | 7.57M | 9.39M | 10.65M | 9.87M | 10.20M | 9.53M | 9.38M | 8.55M | 7.91M | 4.75M | 6.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.14M | 3.46M | 3.15M | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Operating Income | -23.23M | -38.70M | -36.77M | -45.04M | -43.71M | -53.23M | -52.15M | -41.50M | -26.55M |
| Net Income | -23.23M | -38.98M | -36.70M | -44.78M | -44.16M | -53.01M | -50.73M | -40.67M | -26.60M |
| Diluted EPS | - | - | - | - | -1.41 | -1.49 | -1.11 | -0.72 | -0.28 |
| R&D Expense | 18.90M | 28.54M | 27.49M | 33.55M | 41.35M | 38.58M | 40.80M | 36.30M | 37.74M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 66.95M | 45.36M | 71.61M | 99.53M | 83.40M | 91.28M | 61.53M | 32.19M | 42.21M |
| Total Equity | 15.17M | 61.61M | 33.97M | 54.58M | 78.91M | 65.49M | 65.68M | 37.09M | 17.50M | 26.43M |
| Cash & Equivalents | - | - | 20.80M | 44.29M | 74.87M | 64.37M | 51.61M | 48.51M | 22.46M | 27.14M |
| Long Term Debt | - | - | - | - | - | 0 | 8.04M | 4.20M | 0 | - |
| Total Liabilities | - | 5.35M | 11.39M | 17.02M | 20.62M | 17.91M | 25.60M | 24.45M | 14.69M | 15.78M |
| Current Liabilities | - | 5.35M | 6.22M | 11.66M | 16.32M | 12.79M | 11.55M | 17.08M | 13.69M | 13.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.14M | -26.41M | -30.80M | -32.49M | -38.84M | -41.81M | -39.96M | -36.33M | -21.69M |
| Investing Cash Flow | -1.20M | -20.35M | 3.45M | 4.46M | 9.11M | -24.61M | 25.00M | 32.00K | 75.00K |
| Financing Cash Flow | 62.00M | 4.18M | 50.79M | 58.61M | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Capital Expenditure | -1.03M | -1.85M | -46.35K | -595.26K | -913.04K | -171.00K | -0 | -66.00K | -177.00K |
| Free Cash Flow | -13.17M | -28.27M | -30.84M | -33.09M | -39.75M | -41.98M | -39.96M | -36.40M | -21.86M |
| Share Buybacks | - | - | 91.03K | 271.05K | 750.13K | 200.00K | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -3,386.7% | -1,063.2% | -1,428.0% | -292.6% | -4,275.1% | -949.9% | -446.9% | -96.7% |
| Net Margin % | - | -3,411.5% | -1,061.2% | -1,419.8% | -295.6% | -4,257.8% | -924.1% | -438.0% | -96.9% |
| ROE % | -37.7% | -114.7% | -67.2% | -56.8% | -67.4% | -80.7% | -136.8% | -232.4% | -100.6% |
| ROCE % | -37.7% | -98.9% | -61.3% | -54.1% | -61.9% | -66.8% | -117.3% | -224.3% | -92.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CUE
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPMVJ3dFJqLU5oMjdRLUlIUFUtTzNrMEZ2TjU4MFFyeURTWmRRWE5zVTVfVUkzaEVmN01KTG4tTHFBR1FHVUhkd0dNYkVqb2tVSmxkbFB3V3Nxc3FVc2NSOGxzNTVuWVRIalh6aTRKNFlYZXlTckdqZWx0Z01ZakQybHFqOHE4V0JoU2xCNm…
Cue Biopharma Inc - Google
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE15T050N0lJZHhJcnBvWjlGeG9ZYXlpaVdENlBnSWJJWHo1S19hVnZBUjFDU2U1UENsVHB6Y3B6NFBhb3N0SmJLQkQ0ZUtTN2tkM1c2b1JodnZieHc?oc=5" target="_blank">Cue Biopharma Inc</a> <font color…
Cue Biopharma (CUE) hires James Ahlers as CFO with equity and severance package - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSEE3SVFPZzZQcWF3MzFiclUxeldxdU90SkJmNGZlTjFCQXNaQXFUZGFDNmotV0NId01uTGxQUkx2Z0dRUmVOaFptSFlXWGhjSzV0ekJFSXZDZUFGTEtLRGlxMGJVVDRBSW5XUHZUcV9QZUQ4dl9vZlhHZlVMcnBzTkxobUJHa04wTjdVMm…
Cue Biopharma Appoints James M. Ahlers as Chief Financial Officer - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOa21sT05UMTRUbHNnelpkeE1YcjNlRzVOS2pDT0RINmpDRnF3NUNhdXFBWVVqTkQ2SXNhMGZ6TExUOFpUSFNraEhxdjlWQm5PaGxYdjVLam1aR1FFSXNHMFZveXNONzFfeDZCNnJkbXBsMW9oU3VTUUtNS0w1RHAwcVhFTmN3SkZrd0tQSG…
CUE|Cue Biopharma Inc|Price:27.290|Chg%:+0.450 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE05ZGJyZTRrc1lWNzg3SVdoeDBTRTM1a3VtUUFuN1ZNUGlFeVp6MzdHMmhDMG9XNkl0ajlfMHVOWEhWcERhQXRYQ0lGbEFEcklzOTI1WWRrYms?oc=5" target="_blank">CUE|Cue Biopharma Inc|Price:27.290|Chg%:+0.450</…
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQR09FT2FQMnc0cDJYRXRxR2lOcmVfMkNPRFgzbE95RlMzWmVqVVZGeVdQYXZvX0JOYjU3RXpPVkdhaG5uV1JVTC10OGt2Z3Z5cUN1MXI3WXFrSUJOdUZ6WEVLNUc2dktac3cyU21KTFhlR2xuRG5CWXhLenV1Q3hBVzBWSzBJcEszUEdNUX…
CUE — Frequently Asked Questions
What is the current share price of CUE?
As of 2026-08-05 17:25 PDT, CUE trades at $26.65 on NASDAQ/NYSE. Its 52-week range is $5.31 to $36.78.
What is the P/E ratio of CUE?
CUE trades at a trailing price-to-earnings (P/E) ratio of -95.18.
What is the return on equity (ROE) of CUE?
CUE has a return on equity (ROE) of -100.64%. Its return on capital employed (ROCE) is -92.46%.
Is CUE a good stock to buy?
This page provides a data-driven analysis of CUE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.